In patients with detectable beta‐cell reserve, unsatisfactory glucose control (HbA1c 8.3%), excess weight, and intermediate diabetes duration (12 years), Dulaglutide 1.5 mg/week as an adjunct to continuous subcutaneous insulin injection led to remarkable weight loss (−5.6 kg) compared to placebo (−0.5 kg) due to a significant calorie restriction (−400 kCal/day), especially from lipid intake after 24 weeks of treatment. The gene discussed is INS; the disease is diabetes mellitus.